A Multicenter, Open, Comparative Study on Vaginal Dysbiosis in Premenopausal Women (DISPALOMA)

Multicenter, open, comparative study, where all eligible patients with vaginal dysbiosis (vaginal pH >4.5) will be assigned to one of the 3 study groups (1:1:1) according to the randomization list for random assignment to groups B and C:

A. Symptomatic patients: Treatment with Palomacare® vaginal gel for 6 days B. Asymptomatic patients: Treatment with Palomacare® vaginal gel for 6 days C. Asymptomatic patients: Monitored follow-up

2 visits will be made throughout the study: visit 1 (initial visit, between days 9 and 15 of the menstrual cycle) and visit 2 (final visit, within 5 days after the end of treatment or equivalent in the case of the monitored follow-up group, always before the next menstruation).

The study will consist of two phases; the first phase or PILOT, where 30 patients (10 per group) will be included with the intervention of 2 centers, and a second phase or EXTENSION, where 60 additional patients (20 per group) will be included, obtaining a total of 90 patients (30 per group) at the end of the study.

Inclusion criteria

• Between 18 and 45 years of age, inclusive.
• Who are attending a gynecological visit for any reason and who are in the first phase of the menstrual cycle, between the end of menstruation and before ovulation (approximately between days 9 and 15).
• With regular menstrual cycles of between 24 and 35 days.
• Who are able to understand and sign the informed consent after the nature of the study has been fully explained to them.
• With a vaginal pH higher than 4.5 with or without symptoms

Exclusion criteria

• Diagnosis of another vaginal or vulvar condition that may confuse the interpretation of the response to the investigational product (erosive lichen planus, inflammatory desquamative vaginitis, or contact dermatitis involving the vulvar epithelium).
• Diagnosis of cervical intraepithelial neoplasia (CIN), cervical carcinoma, or endometrial neoplasia.
• Active genitourinary infections (VVC, N. gonorrhoeae, C. trachomatis, or T. vaginalis) at the time of inclusion or within 15 days prior to inclusion in the study.
• Active genital lesions (ulcers or vesicles compatible with herpes or warts) or genital bleeding.
• Pregnant patients or in the immediate postpartum period (up to 40 days).
• Contraception with copper IUD.
• Use of oral or topical antibiotics, or vaginal antifungals in the two weeks prior to the initial visit.
• Planned immunosuppressive therapy.
• Decompensated chronic diseases (diabetes, epilepsy, high blood pressure, etc.).
• Use of any other experimental drug or device during the 30 days prior to selection.
• Formal contraindication for the use of the product, such as hypersensitivity to any of the components of the study treatments.
• Inability, at the discretion of the researcher, to comply with the requirements of the study, either due to follow-up problems or due to psychophysical characteristics.